What is the dosage and usage of Ofloxacin (fluoroquinolone antibiotic) for treating bacterial infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ofloxacin Dosage and Usage for Bacterial Infections

For treating bacterial infections, ofloxacin is typically administered at 200-400 mg orally every 12 hours, with specific dosages depending on the type of infection being treated. 1

Standard Dosing Regimens by Infection Type

  • Respiratory Tract Infections:

    • Acute bacterial exacerbation of chronic bronchitis: 400 mg every 12 hours for 10 days (800 mg daily) 1
    • Community-acquired pneumonia: 400 mg every 12 hours for 10 days (800 mg daily) 1
  • Skin and Skin Structure Infections:

    • Uncomplicated infections: 400 mg every 12 hours for 10 days (800 mg daily) 1
  • Sexually Transmitted Infections:

    • Acute, uncomplicated gonorrhea: 400 mg as a single dose 2, 1
    • Nongonococcal cervicitis/urethritis due to C. trachomatis: 300 mg every 12 hours for 7 days 1
    • Mixed infection of urethra and cervix due to C. trachomatis and N. gonorrhoeae: 300 mg every 12 hours for 7 days 1
    • Acute pelvic inflammatory disease: 400 mg every 12 hours for 10-14 days 1
  • Urinary Tract Infections:

    • Uncomplicated cystitis due to E. coli or K. pneumoniae: 200 mg every 12 hours for 3 days 1
    • Uncomplicated cystitis due to other approved pathogens: 200 mg every 12 hours for 7 days 1
    • Complicated UTIs: 200 mg every 12 hours for 10 days 1
    • Prostatitis due to E. coli: 300 mg every 12 hours for 6 weeks 1, 3

Special Population Considerations

  • Patients with Impaired Renal Function: Dosage adjustment required based on creatinine clearance 1:

    • Creatinine clearance 20-50 mL/min: Normal unit dose given once daily (every 24 hours)
    • Creatinine clearance <20 mL/min: Half the usual recommended unit dose given once daily
  • Patients with Cirrhosis: Maximum daily dose should not exceed 400 mg due to reduced excretion in patients with severe liver function disorders 1

Administration Guidelines

  • Antacids containing calcium, magnesium, or aluminum; sucralfate; divalent or trivalent cations (iron); multivitamins containing zinc; or didanosine should not be taken within 2 hours before or after taking ofloxacin 1

Efficacy Considerations

  • Ofloxacin achieves good concentrations in genitourinary tract tissues and fluids, making it particularly effective for urinary tract infections 4
  • Bacteriological response rates exceed 80% in uncomplicated UTIs and 70% in complicated UTIs 4
  • For prostatitis, ofloxacin has shown 100% microbiologic cure rates in preliminary studies 3

Antimicrobial Spectrum

  • Good activity against most Enterobacteriaceae, Staphylococcus saprophyticus, methicillin-susceptible S. aureus, N. gonorrhoeae, and C. trachomatis 4
  • Limited activity against enterococci, Serratia marcescens, Pseudomonas aeruginosa, and many anaerobes 4
  • High concentrations achieved in urine ensure activity against most urinary tract pathogens 4, 5

Resistance Concerns

  • Quinolone-resistant N. gonorrhoeae (QRNG) has been reported in various parts of the world 2
  • Resistance of P. aeruginosa to ofloxacin can develop during treatment (reported in 15% of isolates) 6
  • In areas with high resistance rates, cephalosporins may be preferred over fluoroquinolones 2

Common Adverse Effects

  • Most common adverse events are gastrointestinal, neurological, and dermatological 4
  • Insomnia has been reported (27% in one study) and may respond to dose reduction 6
  • Lower incidence of photosensitivity and tendinitis compared to some other fluoroquinolones 4

Ofloxacin's bactericidal activity, broad spectrum coverage, and favorable pharmacokinetics make it an effective option for various bacterial infections when used according to appropriate dosing guidelines and with consideration of local resistance patterns.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Ofloxacin: in vitro and in vivo activity.

Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, 1987

Research

Oral ofloxacin therapy of infections due to multiply-resistant bacteria.

Diagnostic microbiology and infectious disease, 1991

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.